First‐line PD‐1/PD‐L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non‐squamous non‐small cell lung cancer: A Bayesian network meta‐analysis of randomized controlled trials

Chemotherapy in combination with immune checkpoint inhibitor (ICI) or bevacizumab has demonstrated a superior effect for non‐squamous non‐small cell lung cancer (NS‐NSCLC). There are still few randomized controlled trials (RCTs) investigating the differences between ICI plus chemotherapy (ICI‐chemot...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Jinzhao, Lu, Jiangyue, Zhang, Zhibo, Wang, Yuan, Li, Xiaoyan, Zhang, Sujie, Mu, Shuai, Zhi, Xiaoyu, Ge, Xiangwei, Lu, Di, Hu, Yi, Wang, Jinliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119358/
https://www.ncbi.nlm.nih.gov/pubmed/35315579
http://dx.doi.org/10.1002/cam4.4589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119358/
https://www.ncbi.nlm.nih.gov/pubmed/35315579
http://dx.doi.org/10.1002/cam4.4589

Ejemplares similares